ArticlePloS one2026
Cardiologists' perspectives on pharmacogenomics implementation in a hybrid health system: A qualitative study from the United Arab Emirates.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacogenomics (PGx) can optimise cardiovascular therapy, yet routine integration in cardiology remains limited. In the United Arab Emirates, a hybrid public-private health system, the real-world PGx use is still emerging. However, there is limited understanding of how cardiologists perceive and navigate PGx implementation within such complex health system contexts.
objectiveTo examine cardiologists' perspectives on the feasibility, barriers, and facilitators of implementing PGx using the Consolidated Framework for Implementation Research (CFIR).
methodsA qualitative study using an abductive analytical approach was conducted through semi-structured interviews with 15 cardiologists from public and private institutions. Participants were recruited via purposive, convenience, and snowball sampling. Interviews were transcribed verbatim and thematically analysed in NVivo. The CFIR guided the analysis across intervention characteristics, outer setting, inner setting, individual characteristics, and process.
resultsClinicians expressed strong conceptual support for PGx, especially in higher-risk scenarios, but reported limited hands-on exposure and confidence. Barriers included perceived test complexity, cost, and lack of reimbursement; insufficient laboratory capacity and EHR integration; unclear workflows and role ownership; and turnaround times misaligned with acute care. Outer-setting constraints (ambiguous policy signals and payer criteria) and inner-setting variability (resources, leadership engagement, and communication pathways) further limited uptake. Reported facilitators included multidisciplinary service models (with input from pharmacists and genetics), targeted case-based training, initial deployment in non-acute contexts, and the structured capture of results with EHR-embedded clinical decision support.
conclusionsPGx implementation in cardiology within the UAE is shaped by structural, organisational, and workforce-level gaps. Addressing these through targeted clinical guidance, improved training, stronger reimbursement mechanisms, enhanced laboratory capacity, and integrated digital decision support may enable more equitable and scalable adoption. These findings provide actionable insights for health systems seeking to operationalise PGx within diverse or hybrid healthcare contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.